These in vitro and in vivo findings (Figs. 6 and 7) suggest that inhibition of MEK1/2 suppresses IGF-1R-inhibition-induced p70S6K1 activation in colon tumor cells, providing a new strategy for colon cancer therapy. Here, MAP2K1 is linked to colonic neoplasm.